CIS 인슐린 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 용도별, 유통 채널별, 지역별, 부문별 시장 규모, 점유율 및 동향 분석 보고서 : 예측(2024-2030년)

CIS Insulin Market Growth & Trends:

The CIS insulin market size is expected to reach USD 4.67 billion by 2030, registering a CAGR of 5.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

CIS Insulin Market Report Highlights:

• Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats
• Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins.
• Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region.
• Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body's functions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. CIS Insulin Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. CIS Insulin Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. CIS Insulin Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. CIS Insulin Market: Product Movement Analysis, USD Million, 2023 & 2030
• 4.3. Rapid-acting Insulin
  • 4.3.1. Rapid-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Long-acting Insulin
  • 4.4.1. Long-acting Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Combination Insulin
  • 4.5.1. Combination Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Biosimilar
  • 4.6.1. Biosimilar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Other Products
  • 4.7.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. CIS Insulin Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. CIS Insulin Market: Type Movement Analysis, USD Million, 2023 & 2030
• 5.3. Human Insulin
  • 5.3.1. Human Insulin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Insulin Analog
  • 5.4.1. Insulin Analog Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. CIS Insulin Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. CIS Insulin Market: Application Movement Analysis, USD Million, 2023 & 2030
• 6.3. Type I Diabetes
  • 6.3.1. Type I Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Type II Diabetes
  • 6.4.1. Type II Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. CIS Insulin Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. CIS Insulin Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
• 7.3. Hospital Pharmacies
  • 7.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Retail & Specialty Pharmacies
  • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Other Distribution Channels
  • 7.5.1. Other Distribution Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. CIS Insulin Market: Regional Estimates & Trend Analysis

• 8.1. CIS Insulin Market Share, By Region, 2023 & 2030, USD Million
• 8.2. Commonwealth of Independent States (CIS)
  • 8.2.1. CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. Russia
    • 8.2.2.1. Russia CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Poland
    • 8.2.3.1. Poland CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Turkey
    • 8.2.4.1. Turkey CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.5. Ukraine
    • 8.2.5.1. Ukraine CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.6. Uzbekistan
    • 8.2.6.1. Uzbekistan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.7. Belarus
    • 8.2.7.1. Belarus CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.8. Kazakhstan
    • 8.2.8.1. Kazakhstan CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.9. Rest of CIS
    • 8.2.9.1. Rest of CIS Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Eli Lilly and Company
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/Strategic Initiatives
  • 9.4.2. Sanofi S.A.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/Strategic Initiatives
  • 9.4.3. Boehringer Ingelheim International GmbH
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/Strategic Initiatives
  • 9.4.4. Oramed Pharmaceuticals Inc.
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/Strategic Initiatives
  • 9.4.5. Novo Nordisk A/S
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/Strategic Initiatives
  • 9.4.6. Merck & Co., Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/Strategic Initiatives
  • 9.4.7. Bristol-Myers Squibb Company
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/Strategic Initiatives
  • 9.4.8. Novartis AG
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/Strategic Initiatives